FDG-PET detected thyroid incidentalomas: Need for further investigation?

Annals of Surgical Oncology

Volumn 14, Issue 1, 2007, Pages 239-247

  Are, Chandrakanth ^a   Hsu, John F ^b   Schoder, Heiko ^a   Shah, Jatin P ^a   Larson, Steve M ^a   Shaha, Ashok R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WYCKOFF HEIGHTS MEDICAL CENTER   (United States)

Author keywords

FDG PET scan; Incidentalomas; Risk of malignancy; Thyroid

Indexed keywords

FLUORODEOXYGLUCOSE;

ASPIRATION BIOPSY; CANCER PATIENT; CANCER RISK; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; THYROID CARCINOMA; THYROID DISEASE; THYROID INCIDENTALOMA;

BIOPSY, FINE-NEEDLE; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENTAL FINDINGS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYROID NEOPLASMS;

EID: 33845649452     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9181-y     Document Type: Review

References (25)

1. Cohen MS, Arslan N, Dehdashti F, Doherty G, Lairmore TC, Brunt M, Moley JF. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001; 130(6):941-946
2. 18F-Fluorodeoxyglusocse positron emission tomography for cancer screening in healthy subjects. Anticancer Research 2005; 25: 1421-1426
3. 18F- Fluorodeoxyglusocse uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentalomas. Laryngoscope 2005; 115:1074-1078
4. Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005; 46(5):752-757
5. 18F-Fluorodeoxyglusocse positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endo & Met 2005; 88(9): 4100-4104
6. Van den Bruel A, Maes A, De Potter T, et al. Clinical relevance of thyroid fluorodeoxyglucose-Whole Body positron emission tomography incidentalomas. J Clin Endo & Met 2005; 87(4): 1517-1520
7. Shiga T, Tsukamoto E, Nakada K, et al. Comparison of (18) F-FDG, (131)I-Na, and (201)T1 in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 2001; 42(3):414-419
8. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, et al. Utility of fluorine-18-fluorodeoxyglusocse positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg 2000; 179(6): 457-461
9. Ruiz Franco-Bauz JV, Borrego Dorado I, Gomez Camarero P, Rodriguez Rodriguez JR, Vazquez Albertino RJ, Navarro Gonzalez E, Astorga Jiminez R. F-18-fluorodeoxyglusocse positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan. Rev Esp Med Nucl 2005; 24(1): 5-13
10. de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004; 11(8): 786-794
11. Diehl M, Graichen S, Menzel C, Lindhorst E, Grunwald F. F-18 FDG PET in insular thyroid cancer. Clin Nucl Med 2003; 28(9): 728-731
12. Chen YK, Liu FY, Yen RF, Kao CH. Compare FDG-PET and Tc-99m tetrofosmin SPECT to detect metastatic thyroid carcinoma. Acad Radiol 2003; 10(8): 835-839
13. Erdi YE, Nehmeh SA, Mulnix T, Humm JL, Watson CC. PET performance measurements for an LSO-based combined PET/CT scanner using the National Electrical Manufacturers Association NU 2-2001 standard. J Nucl Med 2004; 45(5):813-821
14. Mawlawi O, Podoloff DA, Kohlmyer S, et al. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med 2004; 45(10):1734-1742
15. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. Am J Roentgenol 1997; 169:1675
16. Shreve PD, Anzai Y, Wahk RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19:61
17. Yasuda S, Shohtsu A, Ide M, et al. Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology 1998; 207:775
18. Boerner AR, Voth I, Theissen P, et al. Glucose metabolism of the thyroid in Graves' disease measured by F-18-fluoro-deoxyglusocse positron emission tomography. Thyroid 1998; 8:765
19. Hsu CH, Liu RS, Wu CH, Chen SM, Shih LS. Complementary role of 18F-fluorodeoxyglusocse positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer. J Formos Med Assoc 2002; 101(7):459-467
20. Diehl M, Risse JH, Brandt-Mainz K, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001; 28(11):1671-1676
21. Mitchell J, Parangi S. The thyroid incidentalomas: an increasingly frequent consequence of radiologic imaging. Semim Ultrasound CT MRI 2005; 26:37-46
22. Kim EK, Park CS, Chung WY, et al. New Sonographic Criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR AM J Roentgenol 2002; 178:687-691
23. Tomimori EK, Camargo RY, Bisi H, Medeiros-Neto G. Combined ultrasonographic and cytological studies in the diagnosis of thyroid nodules. Biochimie 1999; 81:447-452
24. Dario Ramos C, Chisin R, Yeung HWD, Larson SM, Macapinlac HA. Incidental Focal Thyroid Uptake on FDG positron emission tomographic scans may represent a second primary tumor. Clin Nucl Med 2001; 26(3):193-197
25. Kresnik E, Gallowitsch HJ, Mikosch P, et al. Fluorine-18- fluorodeoxyglusocse positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 2003; 133:294-299